Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)
Price to Earnings (P/E)
Price to Operating Profit (P/OP)
Price to Sales (P/S)
Price to Book Value (P/BV)

Illumina Inc., historical price multiples (quarterly data)

		Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020		Dec 29, 2019	Sep 29, 2019	Jun 30, 2019	Mar 31, 2019		Dec 30, 2018	Sep 30, 2018	Jul 1, 2018	Apr 1, 2018		Dec 31, 2017	Oct 1, 2017	Jul 2, 2017	Apr 2, 2017		Dec 31, 2016	Oct 2, 2016	Jul 3, 2016	Apr 3, 2016
	Price to earnings (P/E)
	Price to operating profit (P/OP)
	Price to sales (P/S)
	Price to book value (P/BV)

Valuation ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Illumina Inc.’s P/E ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Illumina Inc.’s P/OP ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Illumina Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return.	Illumina Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.

Illumina Inc., historical P/E calculation (quarterly data)

		Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020		Dec 29, 2019	Sep 29, 2019	Jun 30, 2019	Mar 31, 2019		Dec 30, 2018	Sep 30, 2018	Jul 1, 2018	Apr 1, 2018		Dec 31, 2017	Oct 1, 2017	Jul 2, 2017	Apr 2, 2017		Dec 31, 2016	Oct 2, 2016	Jul 3, 2016	Apr 3, 2016
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Net income attributable to Illumina stockholders (in millions)
	Earnings per share (EPS)²
	Share price^1, 3
	Valuation Ratio
	P/E ratio⁴
	Benchmarks
	P/E Ratio, Competitors⁵
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Data adjusted for splits and stock dividends.

² Q4 2020 Calculation
EPS = (Net income attributable to Illumina stockholders_{Q4 2020} + Net income attributable to Illumina stockholders_{Q3 2020} + Net income attributable to Illumina stockholders_{Q2 2020} + Net income attributable to Illumina stockholders_{Q1 2020}) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

³ Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.

⁴ Q4 2020 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =

⁵ Click competitor name to see calculations.

Valuation ratio	Description	The company
P/E ratio	The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings.	Illumina Inc.’s P/E ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.

Illumina Inc., historical P/OP calculation (quarterly data)

		Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020		Dec 29, 2019	Sep 29, 2019	Jun 30, 2019	Mar 31, 2019		Dec 30, 2018	Sep 30, 2018	Jul 1, 2018	Apr 1, 2018		Dec 31, 2017	Oct 1, 2017	Jul 2, 2017	Apr 2, 2017		Dec 31, 2016	Oct 2, 2016	Jul 3, 2016	Apr 3, 2016
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Income from operations (in millions)
	Operating profit per share²
	Share price^1, 3
	Valuation Ratio
	P/OP ratio⁴
	Benchmarks
	P/OP Ratio, Competitors⁵
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Data adjusted for splits and stock dividends.

² Q4 2020 Calculation
Operating profit per share = (Income from operations_{Q4 2020} + Income from operations_{Q3 2020} + Income from operations_{Q2 2020} + Income from operations_{Q1 2020}) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

³ Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.

⁴ Q4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =

⁵ Click competitor name to see calculations.

Valuation ratio	Description	The company
P/OP ratio	Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit.	Illumina Inc.’s P/OP ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.

Illumina Inc., historical P/S calculation (quarterly data)

		Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020		Dec 29, 2019	Sep 29, 2019	Jun 30, 2019	Mar 31, 2019		Dec 30, 2018	Sep 30, 2018	Jul 1, 2018	Apr 1, 2018		Dec 31, 2017	Oct 1, 2017	Jul 2, 2017	Apr 2, 2017		Dec 31, 2016	Oct 2, 2016	Jul 3, 2016	Apr 3, 2016
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Revenue (in millions)
	Sales per share²
	Share price^1, 3
	Valuation Ratio
	P/S ratio⁴
	Benchmarks
	P/S Ratio, Competitors⁵
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Data adjusted for splits and stock dividends.

² Q4 2020 Calculation
Sales per share = (Revenue_{Q4 2020} + Revenue_{Q3 2020} + Revenue_{Q2 2020} + Revenue_{Q1 2020}) ÷ No. shares of common stock outstanding
= ( + + + ) ÷ =

³ Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.

⁴ Q4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =

⁵ Click competitor name to see calculations.

Valuation ratio	Description	The company
P/S ratio	An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative.	Illumina Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.

Illumina Inc., historical P/BV calculation (quarterly data)

		Dec 31, 2020	Sep 27, 2020	Jun 28, 2020	Mar 29, 2020		Dec 29, 2019	Sep 29, 2019	Jun 30, 2019	Mar 31, 2019		Dec 30, 2018	Sep 30, 2018	Jul 1, 2018	Apr 1, 2018		Dec 31, 2017	Oct 1, 2017	Jul 2, 2017	Apr 2, 2017		Dec 31, 2016	Oct 2, 2016	Jul 3, 2016	Apr 3, 2016
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Total Illumina stockholders’ equity (in millions)
	Book value per share (BVPS)²
	Share price^1, 3
	Valuation Ratio
	P/BV ratio⁴
	Benchmarks
	P/BV Ratio, Competitors⁵
	Abbott Laboratories
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Pfizer Inc.
	Regeneron Pharmaceuticals Inc.
	Vertex Pharmaceuticals Inc.
	Zoetis Inc.

¹ Data adjusted for splits and stock dividends.

² Q4 2020 Calculation
BVPS = Total Illumina stockholders’ equity ÷ No. shares of common stock outstanding
= ÷ =

³ Closing price as at the filing date of Illumina Inc.’s Quarterly or Annual Report.

⁴ Q4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =

⁵ Click competitor name to see calculations.

Valuation ratio	Description	The company
P/BV ratio	The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return.	Illumina Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then increased from Q3 2020 to Q4 2020 exceeding Q2 2020 level.

	Illumina Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

Illumina Inc. (NASDAQ:ILMN)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Historical Valuation Ratios (Summary)

Price to Earnings (P/E)

Price to Operating Profit (P/OP)

Price to Sales (P/S)

Price to Book Value (P/BV)

Illumina Inc. (NASDAQ:ILMN)

Common Stock Valuation Ratios (Price Multiples)Quarterly Data

Historical Valuation Ratios (Summary)

Price to Earnings (P/E)

Price to Operating Profit (P/OP)

Price to Sales (P/S)

Price to Book Value (P/BV)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data